Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Major Shareholder Announcement

07/21/2021 | 12:59pm EDT

Company Announcement

  • Major shareholder announcement for Genmab A/S

Copenhagen, Denmark; July 21, 2021 Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Artisan Partners Limited Partnership has informed us that, as of July 16, 2021, Artisan Partners Limited Partnership holds the voting rights to 3,261,591 shares in Genmab A/S, which amounts to 4.97% of the share capital and voting rights in Genmab A/S.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.

Contact:        
Marisol Peron, Senior Vice President, Global Investor Relations & Communications
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.


Company Announcement no. 59
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment


Primary Logo


ę GlobeNewswire 2021
All news about GENMAB A/S
08:00aGENMAB A/S : RBC Lifts Price Target on Genmab to $56 From $55 Amid Tivdak US Approval, Pot..
MT
09/22GENMAB A/S : (English translation of Articles of Association) (Form 6-K)
PU
09/22GENMAB A/S : Articles of association dated September 21, 2021 – English
PU
09/22PRESS RELEASE : Pfizer and BioNTech Expand -3-
DJ
09/22GENMAB A/S : Investor Presentation - September 2021
PU
09/21GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise (Form 6-K..
PU
09/21Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
09/21SEAGEN : Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin..
AQ
09/21SEAGEN : Genmab Win Accelerated US FDA Nod For Cervical Cancer Drug
MT
09/20GENMAB A/S : TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor,..
PU
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Financials
Sales 2021 8 042 M 1 266 M 1 266 M
Net income 2021 2 268 M 357 M 357 M
Net cash 2021 15 360 M 2 418 M 2 418 M
P/E ratio 2021 82,5x
Yield 2021 -
Capitalization 179 B 28 112 M 28 132 M
EV / Sales 2021 20,3x
EV / Sales 2022 15,1x
Nbr of Employees 1 029
Free-Float 94,9%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 733,00 DKK
Average target price 2 770,87 DKK
Spread / Average Target 1,39%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S12.87%28 627
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.31%47 634